Objective: The objective of this study was to design and identify the novel promising anti-diabetic agents based on the naturally existing potent insulin secretagogue coixol that can improve the potency overcome the adverse effects of existing medicines. Methods: The Auto Dock Vina (ADT) 1.5.6 and PyMOL software were used for molecular docking and visualization purposes. The molecular structures were drawn in Chem Draw 16.0 and by the help of Chem Bio draw three dimensions, all structures were energy minimized by MM2 method and converted to PDB extension file which is readable at the ADT interface. Result: Total 254 designed molecules from each series 1–4 were checked for binding score with the receptor 5yw7. Out of that total 12 molecules from each series were selected on the basis of their binding affinity in each series. Among these coixol (Natural product), DP322, DP330, and DP422 were studied in-depth. Conclusion: Coixol-based derivatives which scored best binding affinity such as DP332, DP330, and DP422 were shown promising result on the interaction with the K+ ATP sensitive Potassium channel protein (5yw7). The entire study suggests that these novel coixol-based derived molecules could be a promising lead for the further discovery and investigation of insulin sensitizing agents for the treatment of diabetes.
A stability indicating high performance liquid chromatographic method has been developed and validated for the anti-diabetic drugs Rosiglitazone, Glimepiride, and Metformin HCl in pharmaceutical dosage forms. Chromatographic separation was achieved on Zorbex SB C-8 (250 X 4.6 mm) 5µ and Hypersil BDS C18 (200 × 4 mm), 5μ column as stationary phase. Mobile phase consisting of 0.023M potassium dihydrogen phosphate and acetonitrile (60:40, v/v) supplied at a flow rate of 1ml/min. Detection was performed using a SPD-20A prominence UV/VIS detector at 230 nm. The retention time of rosiglitazone, glimepiride and metformin hydrochloride was achieved at 2.4 min, 4.5 min and 5.6 min respectively. The method was validated for linearity, precision, accuracy, toughness, specificity, and forced degradation studies and the relative response factor values of rosiglitazone, glimepiride, and metformin determined from linearity study were 0.998 in the combined form. Rosiglitazone, glimepiride, and metformin HCl showed percentage recoveries of 99.73%, 99.81and 100.31%, respectively. The propesd method found to be very effective and stable for the routine analysis of mentioned antidiabetic drugs in pharmaceutical dosage forms.
Pain management has remained one of the most critical challenges in clinical medicine over the past several decades, with narcotics continuing to play a central role in controlling moderate to severe pain. Originating from natural sources such as Papaver somniferum, these compounds have evolved significantly from plant-derived alkaloids to highly potent synthetic opioids. However, despite their therapeutic effectiveness, long-standing concerns such as addiction, tolerance, and life-threatening side effects remain major obstacles. This review presents a comprehensive overview of the historical development of narcotics and recent progress in synthetic pain-relief agents. A broad literature survey was conducted, encompassing peer-reviewed articles, clinical trial data, and historical records, complemented by an independent SAR analysis based on the chemical structures of some of the most potent synthetic derivatives reported to date. Key transitions from traditional opioids to synthetic compounds such are explored, alongside novel clinical advancements like Oliceridine (TRV-130), NKTR-181, and Cebranopadol, which demonstrate promising analgesic efficacy with fewer adverse effects. Additionally, recent preclinical studies on synthetic mu-opioid receptor agonists and dual-receptor targeting compounds are discussed for their therapeutic potential. Overall, ongoing research into safer and more effective synthetic opioids offers a hopeful path forward in advancing analgesic therapy.